Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) EBIT Margin (2020 - 2022)

SELLAS Life Sciences (SLS) has disclosed EBIT Margin for 3 consecutive years, with 1673.5% as the latest value for Q1 2022.

  • On a quarterly basis, EBIT Margin fell 163411.0% to 1673.5% in Q1 2022 year-over-year; TTM through Dec 2022 was 4195.0%, a 386218.0% decrease, with the full-year FY2022 number at 4195.0%, down 386218.0% from a year prior.
  • EBIT Margin was 1673.5% for Q1 2022 at SELLAS Life Sciences, down from 234.37% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 39.39% in Q1 2021 to a low of 1673.5% in Q1 2022.
  • A 3-year average of 541.54% and a median of 226.63% in 2021 define the central range for EBIT Margin.
  • Biggest YoY gain for EBIT Margin was -163411bps in 2022; the steepest drop was -163411bps in 2022.
  • SELLAS Life Sciences' EBIT Margin stood at 218.89% in 2020, then decreased by -7bps to 234.37% in 2021, then plummeted by -614bps to 1673.5% in 2022.
  • Per Business Quant, the three most recent readings for SLS's EBIT Margin are 1673.5% (Q1 2022), 234.37% (Q2 2021), and 39.39% (Q1 2021).